文献速递外周动脉疾病

紫杉醇洗脱自膨式Stentys支架治疗CLI膝下病变的一年结果

One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
PubMed 文献 · J Endovasc Ther · 2017-03-09

前瞻性单臂多中心PES-BTK-70试验评估紫杉醇涂层自膨式镍钛Stentys支架治疗CLI患者胫腓动脉≤50 mm病变的安全性和有效性。70例患者随访显示6个月和1年主要通畅率分别为87.6%和72.6%,1年免于TLR为79.1%,肢体救赎率98.5%,无支架断裂。

要点

  • 紫杉醇洗脱自膨式Stentys支架治疗CLI膝下短病变1年主要通畅率72.6%。
  • 1年免于靶病变血运重建率79.1%,肢体救赎率98.5%。
  • 技术成功率97.1%,12个月内核心实验室未发现支架断裂。

核心结论

  • 紫杉醇洗脱自膨式镍钛Stentys支架在膝下区域安全有效,结果与近期limus洗脱支架试验相似。

研究设计与样本

  • 前瞻性单臂多中心PES-BTK-70试验(NCT01630070)纳入70例CLI患者,评估冠脉Stentys支架治疗胫腓动脉≤50 mm狭窄或闭塞病变。

主要发现

  • 6个月主要通畅率87.6%(95%CI 83.5%~91.7%),1年主要通畅率72.6%(95%CI 66.9%~78.3%)。
  • 1年免于TLR率79.1%(95%CI 73.9%~84.3%),肢体救赎率98.5%(95%CI 97.0%~100.0%)。
  • 技术和手术成功率97.1%(68/70),12个月内核心实验室未发现支架断裂。

关键数值与推荐

  • 主要终点为6个月(双功超声)和12个月(血管造影)主要通畅率。

临床怎么用

  • 对于CLI患者胫腓动脉≤50 mm的狭窄或闭塞病变,可考虑使用紫杉醇洗脱自膨式Stentys支架。

局限性

  • 单臂设计,无对照组,样本量70例,随访1年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the efficacy of the paclitaxel-coated, self-expanding, nitinol Stentys Stent System in tibioperoneal lesions ≤50 mm long. METHODS: The prospective, single-arm, multicenter PES-BTK-70 trial ( ClinicalTrials.gov identifier NCT01630070) evaluated the safety and efficacy of the coronary Stentys Stent System in the treatment of a stenotic or occlusive lesion ≤50 mm long in the tibioperoneal arteries of patients with critical limb ischemia (CLI). Between January 2012 and May 2013, 70 patients (mean age 74.6±9.4 years; 45 men) with CLI [Rutherford category 4 (37, 52.9%) or 5 (33, 47.1%)] received a Stentys drug-eluting stent for the treatment of infrapopliteal stenosis (60, 85.7%) or occlusion (10, 14.3%). The mean lesion length was 17.2 mm (4.0-58.5). The primary outcome measures were primary patency at 6 months (duplex ultrasound) and 12 months (angiography). Secondary outcomes included limb salvage and freedom from target lesion revascularization (TLR). Kaplan-Meier estimates of the outcomes are given with the 95% confidence intervals (CI). RESULTS: Technical and procedure success (<30% residual stenosis without major complications) was achieved in 68 (97.1%) of 70 cases. Primary patency was 87.6% (95% CI 83.5% to 91.7%) at 6 months and 72.6% (95% CI 66.9% to 78.3%) at 1 year. Freedom from TLR was 79.1% at 1 year (95% CI 73.9% to 84.3) and limb salvage was 98.5% (95% CI 97.0 to 100.0). No stent fractures were found by core laboratory review of all follow-up imaging data available up to 12 months. CONCLUSION: In this study, the self-expanding, nitinol, paclitaxel-eluting, coronary Stentys stent was found to be safe and effective in the below-the-knee region, with results similar to the most recent limus-eluting stent trials.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bosiers M, Callaert J, Keirse K, et al. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia. J Endovasc Ther. 2017. PMID: 28351310. doi:10.1177/1526602817697319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。